- Home
- MBOT vs XBIT Comparison
MBOT vs XBIT Comparison
Compare MBOT & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBOT | XBIT |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.3M | 69.5M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | MBOT | XBIT |
|---|---|---|
| Price | $2.44 | $2.44 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.75 | N/A |
| AVG Volume (30 Days) | ★ 3.0M | 73.6K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,166.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.93 | $2.09 |
| 52 Week High | $4.67 | $7.24 |
Technical Indicators
Market Signals| Indicator | MBOT | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 54.86 | 48.15 |
| Support Level | $2.31 | $2.15 |
| Resistance Level | $2.48 | $2.65 |
| Average True Range (ATR) | 0.16 | 0.15 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 79.31 | 33.33 |
Price Performance
Historical ComparisonAbout MBOT Microbot Medical Inc.
Microbot Medical Inc is a breakthrough medical device company. The group is focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. With a robust intellectual property portfolio and a deep commitment to innovation, Microbot is shaping the future of endovascular care.
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.